Cite
HARVARD Citation
Borobia, A. et al. (2021). Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 398 (10295), pp. 121-130. [Online].